Cargando…
Engineering monoclonal antibodies for COVID-19 prophylaxis
The therapeutic and prophylactic uses of monoclonal antibodies (mABs) against SARS-CoV-2 are limited by their short half-life and need for intravenous delivery. In this issue, Cobb et al.(1) engineer a neutralizing mAB cocktail with extended half-life that can be delivered intramuscularly to provide...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915435/ https://www.ncbi.nlm.nih.gov/pubmed/35291730 http://dx.doi.org/10.1016/j.medj.2022.02.004 |